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Modulation of mRNA translation via the mammalian target of rapamycin (mTOR) pathway is 
primarily achieved by integrating internal or external signals onto the translation machinery, 
especially on the rate-limiting initiation step during mRNA translation. Subsets of transcripts 
are discriminated by structural and/or sequence features, and encode proteins involved in 
different biological functions. For example, a group of mRNAs with a stretch of uninterrupted 
4-15 pyrimidines following a cytosine after the m7Gppp cap at their 5’ untranslated region 
(5’UTR) are termed as TOP mRNAs, which mainly encode ribosomal proteins and translation 
factors. By developing a luciferase reporter to quantify TOP mRNA translation, this thesis 
provides insight into mTOR-dependent or -independent modulators of TOP mRNA translation. 
These studies also suggest a vast kinase repertoire potentially modulating TOP-mRNA 
translation (Paper II).  
Aberrations in mTOR pathway drive tumorigenesis and development. The first-generation 
allosteric mTOR inhibitors, rapamycin analogs (also called rapalogs), and the second 
generation ATP-competitive kinase mTOR inhibitors have been tested in a wide range of 
tumors as monotherapy or a component of combination therapy. However, either the poor 
potency of the first generation or the toxicity of the second generation makes the clinical benefit 
limited. Based on the prototype of one third-generation mTOR inhibitor, RapaLink-1, we 
produced a series of new mTORC1-selective bi-steric inhibitors through continuous and finely 
tuned pharmaceutical and chemical modifications, which selectively inhibit mTORC1 over 
mTORC2, but retain potent efficacy in suppressing tumor growth (Paper I). Findings within 
Paper I demonstrate that mTORC1 mediates modulation of mRNA translation. 
Immune cells within the tumor microenvironment (TME) represent an indispensable factor 
during tumor cells’ escape from immune surveillance, which occurs via multiple mechanisms, 
including immune cell acquisition of pro-tumor phenotypes. Therefore, immunotherapy, which 
re-activates the immune system towards cancer cells, has emerged as an essential treatment 
option. Paper IV indicates that immune suppression mediated by tumor-associated 
macrophage (TAM) depends on the MNK2/eIF4E axis but not mTOR. The model suggests 
that MNK2 thereby controls translation of a subset of transcripts encoding proteins which in 
turn modulate the TAM phenotype. This finding extends our understanding of how mRNA 
translation contributes to immune cell phenotypes.  
Expression of a functional Von Hippel-Lindau Tumor Suppressor (VHL) protein is commonly 
lost in renal cell carcinoma (RCC). In RCC, there is ample prognosis heterogeneity among 
patients treated with rapalogs, which inhibits mTORC1. Thus, it could be due to acquired 
resistance. Therefore, We examined whether alterations in gene expression in response to 
rapalogs associated with VHL status  (Paper III). As expected, VHL re-expression not only 
caused wide-spread changes in mRNA levels but also alterations in mRNA translation. 
Moreover, translation of transcripts subsets was sensitive to rapamycin only under VHL 
proficiency or VHL deficiency. Further studies will aim to determine whether these differences 
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1.1 GENE EXPRESSION  
Gene expression is one of the most fundamental processes in eukaryotic cells. Genetic 
information stored in double-stranded DNA is transcribed into messenger RNA (mRNA) and 
mRNAs are then translated into proteins in a “DNA-RNA-protein” flow, which is referred to 
as the central dogma of molecular biology (Crick, 1970). Broadly speaking, regulation of gene 
expression drives cell proliferation, tissue differentiation, and organismal development. 
Regulation of gene expression controls timing, position, and amount of a given gene product. 
Narrowly speaking, it starts from transcription, RNA-splicing and -transport from the nucleus 
into the cytosol, to translation, mRNA decay and post-translational modification of a protein. 
For some proteins this is followed by transport to the cell surface or secretion. All these 
processes are dynamic and tightly controlled.  As shown in Figure 1, multiple regulations at 
each step in the gene expression process will confer a specific layer (i.e. genome, transcriptome, 
proteome) of information as an output. Such control of gene expression plays an essential role 
in physiological and pathological conditions. Herein, messenger RNA (mRNA) translation will 
be the focus of this thesis. 
  
 
Figure 1: Overview of the gene expression pathway. Initial steps in gene expression connecting 
genotype to phenotype. Factors that confer control are indicated at the bottom.  
Reprinted with permission from Springer Nature, Nature Reviews Genetics. Buccitelli, C., Selbach, M. mRNAs, proteins and 




Translation is a step-wise and coordinated process by which a polypeptide chain is synthesized 
from a messenger RNA (mRNA), during which ribosomes, transfer RNAs (tRNAs) and 
numerous other factors are engaged. It is one of the most energy-consuming steps as well as 
one of the most complex processes in cellular activity (Buttgereit & Brand, 1995). It can be 
divided into four phases: initiation, elongation, termination and ribosome recycling (Hershey, 
Sonenberg, & Mathews, 2012; Jackson, Hellen, & Pestova, 2010).  
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1.2.1 Translation initiation  
Cap-dependent scanning mechanism for mRNA translation initiation is used by the majority 
of mRNAs in eukaryotes. The process of translation initiation includes the formation of several 
fundamental complexes, as well as the engagement of at least 12 proteins, i.e. eukaryotic 
initiation factors (eIFs) (Figure 2) (Jackson et al., 2010; Marintchev & Wagner, 2004; Merrick 
& Pavitt, 2018; Sonenberg & Hinnebusch, 2009; Thoreen, 2013). First, eIF2, initiator 
methionyl transfer RNA (Met-tRNAi) and GTP form the ternary complex (TC), eIF2-GTP-
Met-tRNAi. This complex joins with the 40S small ribosomal subunit together with other 
eukaryotic initiation factors (eIFs; eIF1, eIF1A, eIF3, eIF5) to form the 43S ribosome pre-
initiation complex (PIC). Secondly, the assembly of the cap-binding complex eIF4F happens 
at the m7GpppN cap. It consists of eIF4E (cap-binding protein), eIF4G (scaffolding protein) 
and eIF4A (helicase). Finally, the 43S PIC is recruited to the 5’ cap through interacting with 
eIF4G to form the 48S ribosome complex, where the 40S ribosomal subunit scans the mRNA 
from the 5’end towards the first start codon (typically AUG, or rarely a near-cognate AUG). 
During this process, eIF4G also interacts with the poly (A)-binding protein (PAPB), which 
stabilizes the mRNA and enhances translation via binding the poly (A) tail of the 3’UTR 
(Ivanov et al., 2016). 
Once AUG recognition occurs, hydrolysis of eIF2-bound GTP is triggered and eIFs (including 
eIF2) are released from PIC. Then the large 60S ribosomal subunit joins to form the 80S 
ribosome, which will enter the translation elongation phase (Hinnebusch, 2014). As translation 
is a cyclic process, inactive eIF2-GDP will be converted to active eIF2-GTP by the guanine 
nucleotide exchange factor eIF2B, to participate in another round of initiation.  
Besides the cap-dependent translation initiation mechanism in eukaryotes, translation initiation 
of some mRNAs is mediated by cap-independent mechanisms such as an internal ribosome 
entry site (IRES) (Hinnebusch, 2014; Jackson et al., 2010). IRESes, which are often in the 
5’UTR, directly recruit ribosomes, bypassing the scanning of 5’UTR, and allow translation to 





Figure 2: Cap-dependent translation initiation process in eukaryotes and regulatory factors of 
TC and eIF4F formation.  
Reprinted with permission from Elsevier, Cell. Nahum Sonenberg, Alan G. Hinnebusch, Regulation of Translation Initiation in 
Eukaryotes: Mechanisms and Biological Targets, Cell, Volume 136, Issue 4, 2009, Pages 731-745, ISSN 0092-8674, 
https://doi.org/10.1016/j.cell.2009.01.042. 
1.2.2 Translation elongation 
Mechanism of elongation is conserved between eukaryotes and bacteria, with more studies 
having been focusing on bacterial systems (Rodnina & Wintermeyer, 2009). Elongation starts 
upon the formation of 80S ribosome at the start codon, which is the start of an open reading 
frame (ORF). Anticodon of Met-tRNAi is base-paired with the start codon in the P site (for 
peptidyl) of the 80S ribosome, while the second codon is present in the A site (aminoacyl). The 
eukaryotic elongation factor eEF1A plays an important role in this phase, as it binds aminoacyl-
tRNA and GTP forming a ternary complex, eEF1A-GTP-aminoacyl-tRNA. Thus, the 
anticodon of a cognate elongating tRNA will be base-paired with the second codon of the 
mRNA in the A site, triggering the hydrolysis of GTP by eEF1A. Released eEF1A-GDP is 
recycled to eEF1A-GTP by the exchange factor eEF1B and aminoacyl-tRNA is accommodated 
into the A site. Peptide bond formation is accompanied with the A- and P-site tRNAs shifting 
into hybrid states, resulting in the acceptor ends of the tRNAs moving to P and E (exit) sites, 
respectively (Behrmann et al., 2015; Budkevich et al., 2011; Moazed & Noller, 1989). 
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Translocation of the tRNAs to the E and P sites is promoted by the elongation factor eEF2. 
Then a deacylated tRNA occupies the E site and the peptidyl-tRNA is in the P site, leaving the 
A site vacant, allowing for the appropriate eEF1A-GTP-aminoacyl-tRNA binding (Dever, 
Dinman, & Green, 2018; Dever & Green, 2012).  
1.2.3 Translation termination and ribosome recycling 
Translation termination happens when a stop codon (UAA, UGA or UAG) enters the A site. 
Two release factors involved in this phase are eRF1 and eRF3 (Alkalaeva, Pisarev, Frolova, 
Kisselev, & Pestova, 2006; Dever & Green, 2012; Jackson, Hellen, & Pestova, 2012). Here, 
eRF1, eRF3 and GTP form an eRF1-eRF3-GTP ternary complex, where eRF1 is responsible 
for recognition of the stop codons and release of the nascent peptide from the P site peptidyl-
tRNA, while eRF3 hydrolyzes the GTP and enhances peptide release. This ternary complex 
will be disassembled and its constituents are ready for recycling. Ribosome recycling is 
mediated by an important protein ABCE1, which splits the 80S ribosome to release the 60S 
subunit, followed by dissociation of deacylated tRNA and mRNA from the 40S subunit (Dever 
& Green, 2012; Hellen, 2018). Ribosomes, mRNAs and tRNA are recycled to participate in 
multiple rounds of translation.  
 
1.3 TRANSLATIONAL CONTROL OF GENE EXPRESSION  
1.3.1 Origins of translational control  
Only a few years after the articulation of the central dogma of molecular biology (CRICK, 
1958), the notion that protein synthesis can be altered via the efficiency of utilization of 
mRNAs to regulate gene expression emerged. In 1961, Jacob and Monod perceived and 
advanced the concept that in the elegant model for transcriptional control, the intermediate 
mRNA plays a key role in protein synthesis. (Jacob & Monod, 1961). Ten years later, 
Humphreys alluded to the “now classical conclusion” that in eggs, upon fertilization, silent 
mRNA is translationally activated (Humphreys, 1971). The earliest use of the term 
“translational control” traces back to 1968, by which date now well-known paradigms of 
translational control had all been established, e.g. developing embryos, reticulocytes, virus-and 
phage-infected cells, etc. The study of translational control increased in the 1960s when a large 
proportion of the translational apparatus was characterized. This signifies the pace in 
advancement of the understanding of protein synthesis (M. B. Mathews, Sonenberg, & 
Hershey, 2000). 
Translational control is defined as a change in the rate (efficiency) of translation of one or more 
mRNAs, i.e., the number of completed protein products per mRNA and unit time (Hershey, 
Sonenberg, & Mathews, 2019; M. B. Mathews et al., 2000). Generally, during protein 
synthesis, the number of translation initiation events per unit time (approximately the number 
of bound ribosomes on one transcript) approximates the number of polypeptides, i.e., protein 
synthesis is determined to a large extent by the initiation rate. Moreover, compared with 
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elongation and termination phases, initiation has been shown to be the rate-limiting step during 
the process under most conditions (Lodish & Jacobsen, 1972; Tsung, Inouye, & Inouye, 1989; 
Walden, Godefroy-Colburn, & Thach, 1981).   
Under certain circumstances, responses via altered transcription cause a delay in implementing 
corresponding changes at the protein level. However, adaption at the translation step can 
happen directly and rapidly. On the other hand, changes at the translational level are mostly 
reversible and fine-tuned, making it an economical and flexible mode in terms of energy cost.  
1.3.2 Principles of general and selective control of translation 
Although direct regulation of translation is not equally studied as transcription, it does play a 
crucial role under certain occasions such as nutrient deprivation and energy stress, and is 
emerging to be more studied in regulation of gene expression. Control of translation is mostly 
regulated at the initiation phase allowing rapid changes of cellular protein levels (translational 
output). Accordingly, a particular layer of output between transcriptome and proteome in 
Figure 1, emerges and is termed as translatome. Theoretically, regulation of eIFs activity 
and/or availability will affect translation of most mRNAs which use the cap-dependent 
scanning mechanism for initiation.  
1.3.2.1 eIF2-GTP-Met-tRNAi ternary complex 
One of the best-characterized examples for regulation of translation initiation is the formation 
of the eIF2-GTP-Met-tRNAi ternary complex, in which eIF2 can be phosphorylated by any of 
four known stress-sensing kinases (Figure 2). In response to a range of physiological changes 
or pathological stimuli, the integrated stress response (ISR) pathway is activated to attenuate 
global protein synthesis while simultaneously triggering a transcriptional program to restore 
cellular homeostasis in eukaryotes (Harding et al., 2003; Ron, 2002). The core event is 
phosphorylation of eIF2α, and the four homologous eIF2α kinases are PKR-like ER kinase 
(PERK, EIF2AK3), double-stranded RNA-dependent protein kinase (PKR, EIF2AK2), heme-
regulated eIF2α kinase (HRI, EIF2AK1), and general control non-derepressible 2 (GCN2, 
EIF2AK4) (Donnelly, Gorman, Gupta, & Samali, 2013; Wek, Jiang, & Anthony, n.d.). For 
instance, the endoplasmic reticulum (ER) is the cellular compartment where folding proteins 
into proper structures occurs. Upon stress, incorrectly folded proteins will accumulate thus 
triggering the ER-stress response (Harding, Zhang, & Ron, 1999), like the unfolded protein 
response (UPR) (Gething & Sambrook, 1992) for relieving the ER stress. Consequently, 
kinases such as PERK phosphorylate eIF2α subunit on Ser51 (Harding et al., 1999; Vattem & 
Wek, 2004). Phosphorylated eIF2-GTP can still participate in translation initiation; however, 
after the release of phosphorylated eIF2-GDP, it will tightly bind and sequester eIF2B, 
abrogating its activity and resulting in the decrease of the available eIF2-GTP-Met-tRNAi 
ternary complex (M. Mathews, Sonenberg, & Hershey, 2007). Although the translation of most 
mRNAs is inhibited through this mechanism, certain mRNAs are stimulated at the translational 
level. For instance, activating transcription factor 4 (ATF4) expression level is increased 
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around 5-fold by PERK activation via an upstream open reading frame (uORF)-mediated 
mechanism (Vattem & Wek, 2004).  
1.3.2.2 eIF4F complex 
In cap-dependent translation initiation, ribosome recruitment is regulated mostly via the 
formation of eIF4F complex, which can be affected by phosphorylation of eIF4E-binding 
proteins (4E-BPs; mostly, 4E-BP1). 4E-BP1 is phosphorylated on multiple sites by mTORC1, 
then dissociates from eIF4E, promoting eIF4E interaction with eIF4G and the assembly of  
eIF4F complex. Thus, eIF4F is a node for integrating upstream signals on translation. In paper 
I, we compared effects of new mTORC1-selective bi-steric inhibitors on the translatome with 
one potent pan-mTOR inhibitor MLN0128. The results indicated the new generation of 
inhibitors showed high selectivity to mTORC1 and fewer side effects but retained potent 
targeting of substrates. On the other hand, eIF4E can be phosphorylated (on Ser209) by 
mitogen-activated protein kinase (MAPK)-interacting protein kinases (MNKs) 1 and 2 
(Pyronnet et al., 1999; Waskiewicz et al., 1999), and phosphorylation of eIF4E is important 
during tumorigenesis (Wendel et al., 2007). Currently, it has been noted that although 
phosphorylation of eIF4E does not have a major impact on global translation, it does partially 
promote translation of a subset of mRNAs encoding proteins involved in tumor metastasis, e.g. 
SNAIL and MMP-3 (N. Robichaud et al., 2014). In paper IV, in a breast cancer mouse model, 
during tumor progression, tumor-associated macrophages (TAMs) are reprogrammed from a 
proinflammatory phenotype towards an antiinflammatory phenotype with augmented 
phosphorylation of eIF4E via a selective translational program depending on MNK2 signaling 
(Bartish et al., 2020). Besides, phosphorylation of other factors such as eIF4G and ribosomal 
protein S6 (rpS6) (rpS6 is activated by S6K, downstream of mTORC1 pathway) has also been 
studied to mediate control of translation (Pende et al., 2004; Raught et al., 2000; Ruvinsky et 
al., 2005).  
1.3.2.3 RNA-binding proteins (RBPs) and microRNAs (miRNAs) 
RNA-binding proteins (RBPs) and microRNAs (miRNAs) are another two categories of factors 
regulating translation. Early studies found that most regulation by RBPs and microRNAs is 
inhibitory (De Melo Neto, Standart, & De Sa, 1995). Currently, more and more RBPs and 
microRNAs are recognized to stimulate translation, while some have dual regulation depending 
on contexts, e.g. La-related protein 1 (LARP1) suppresses translation via binding 5’-end of 
TOP mRNA with DM15 (DM15 is the C-terminal region of LARP1) (Fonseca et al., 2015a; 
Lahr et al., n.d.; Philippe, Vasseur, Debart, & Thoreen, 2018), while its La module (LaMod) 
domain remains constitutively bound to poly A tail-binding protein (PABP) to stabilize TOP 
mRNA, and whereby to facilitate translation (J.-J. Jia et al., 2021a). Due to the natural 
sequence-binding feature for their role in such control, RBPs and miRNAs have the potential 
to selectively regulate certain mRNAs with specific sequence features.  
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1.3.2.4 The TOP-motif enables mTOR-dependent regulation of mRNA translation 
Ribosomal proteins and translation factors are encoded by mRNAs with a stretch of 
pyrimidines following a cytosine after the m7Gppp cap [termed as 5’ terminal oligopyrimidine 
(TOP motif); the corresponding mRNA is termed TOP mRNA] (Hamilton, Stoneley, Spriggs, 
& Bushell, 2006). This feature is necessary and must be in its native position for control of 
TOP mRNA translation (Meyuhas & Kahan, 2015). A series of studies have characterized their 
poor translation in quiescent cells but strong and rapid activation on nutrients refueling such as 
serum, amino acids or by insulin and have pinpointed the mTOR pathway in control of TOP 
mRNA translation (Figure 3) (Hsieh et al., 2012; Thoreen et al., 2012). However, the detailed 
molecular mechanism remains incompletely revealed. Most recently, La-related protein 1 
(LARP1) was proposed for its negative role downstream of mTORC1 signaling to suppress 
TOP mRNA translation, although deletion of it could not completely de-repress the inhibition 
of rapamycin or torin1 on TOP mRNA translation (Aoki et al., 2013; Fonseca et al., 2015a, 
2015b; J.-J. Jia et al., 2021b; Lahr et al., n.d.). Thus, we hypothesized that additional regulators 
exist whose effect on TOP mRNA translation may depend on mTORC1/2 or not. In Paper II, 
we generated a cell line stably expressing luciferase with the RPL23 TOP-motif which 
quantifies TOP mRNA translation. Further, we used this model in a high-throughput screening 
based on a kinome-wide siRNA library, aiming to explore potential targets positively or 
negatively regulating TOP mRNA translation. More details are provided in section 3.1. 
1.3.2.5 mRNAs with long and structured 5’UTR 
Because the mechanism of translation initiation for most mRNAs is cap-dependent, it is natural 
that mRNAs with long and structured 5’UTR are demanding regarding the availability of eIF4F 
complex (Svitkin et al., 2001) due to the need of eIF4A helicase activity (Figure 3). 
Specifically, mRNAs encoding proteins involved in cell growth, proliferation (e.g. cyclins, 
ODC, VEGF and MYC) are among those sensitive to eIF4E (Bhat et al., 2015a; Chu & Pelletier, 
2018; Gandin et al., 2016; Nandagopal & Roux, 2015; Rousseau, Kaspar, Rosenwald, Gehrke, 
& Sonenberg, 1996; Sonenberg & Gingras, 1998; Thoreen, 2013). Consistent with this, 
overexpressed eIF4E has been associated with tumorigenesis and tumor progression (Y. Jia, 
Polunovsky, Bitterman, & Wagner, 2012). Recently, a subset of mRNAs involved in 
mitochondrial function and biogenesis are also emerging to be sensitive to eIF4E, but without 
long and structured 5’UTR, implying mechanism of the eIF4E sensitivity yet to be resolved 
(Gandin et al., 2016; Morita et al., 2013).  
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Figure 3: mTORC1 converges signaling to the translation machinery. Two groups of mRNAs 
are sensitive to mTORC1-mediated regulation: mRNA with TOP motif; mRNA with structured 
5’UTR.  
Reprinted with permission from Taylor & Francis, translation. Nandagopal N, Roux PP. Regulation of global and specific 




1.3.3 Translational control under different contexts 
As mentioned above, multiple external or internal stimuli converge influences on several key 
components of translational apparatus, such as eIF4E and eIF2α. During physiological 
development, cells can be subjected to different stimuli, including hormones, growth factors, 
oxygen levels, nutrient deprivation, etc. Under certain conditions, translational control plays a 
more prominent role in maintaining homeostasis.  
1.3.3.1 Nutrients and hormones converge signals via the mTOR pathway 
1.3.3.1.1 mTOR  
Studies leading to the discovery of mTOR started in the late 1970s with the discovery of 
rapamycin, which was first isolated from the bacterium Streptomyces hygroscopicus (Sehgal, 
Baker, & Vézina, 1975; Vézina & Kudelski, 1975). Functionally, rapamycin was found to 
suppress fungi growth, immune response and tumor growth (Eng, Sehgal, & Vézina, 1984; 
Sehgal et al., 1975). Afterwards, the two identified targeted proteins (encoded by TOR1 and 
TOR2) were named the mechanistic target of rapamycin (mTOR) (Heitman, Movva, & Hall, 
1991). From this point, mTOR has been widely studied and emerged to be a central node to 
converge multiple upstream signaling pathways on cellular anabolic and catabolic activities 
(Liu & Sabatini, 2020). As such, it plays an essential role in sensing nutrient availability to 
maintain cellular homeostasis.  
mTOR is a serine/threonine protein kinase, mainly existing in two complexes named mTORC1 
and mTORC2. These two complexes are distinguished by distinct subunits: Raptor (for 
mTORC1) and Rictor (for mTORC2), as well as by their unique substrates and sensitivity to 
rapamycin (Wullschleger, Loewith, & Hall, 2006). mTORC1 comprises three core components: 
mTOR, mammalian lethal with SEC13 protein 8 (mLST8, also known as GβL) (D. H. Kim et 
al., 2003) and regulatory-associated protein of mTOR (RAPTOR) (D.-H. Kim et al., 2002) 
(Figure 4). RAPTOR works as a scaffolding protein for mTORC1 accessory factor proline-
rich AKT substrate 40KDa (PRAS40) (Sancak et al., 2007), which is an endogenous inhibitor 
of mTORC1, alongside DEP-domain-containing mTOR-interacting protein (DEPTOR) 
(Peterson et al., 2009).  
Structural studies have reported the key residues in the kinase domain of mTOR may only shift 
into a catalytic position after binding the small GTPase Rheb which acts as an essential 
activator of mTOR (Yang et al., 2017). It has also revealed that the basis of mTORC1 inhibition 
by FKBP12, which binds the FKBP12-rapamycin binding (FRB) domain of mTOR, thus 
occluding the binding of substrate with the kinase active site (Yang et al., 2017, 2013). By 
contrast, in mTORC2, in lieu of RAPTOR, the scaffolding protein, RICTOR blocks the FRB 
domain on mTOR (Figure 4), rendering mTORC2 insensitivity to rapamycin. This provides a 
basis for selective targeting approaches. However, it has been noted prolonged rapamycin 
exposure will reduce assembly of mTORC2 via FKBP12-rapamycin binding to free mTOR 
molecule (Sarbassov et al., 2006).  
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Figure 4: Structure of mTORC1(A) and mTORC2(B).  
Modified and Reprinted with permission from Springer Nature, Nature Reviews Molecular Cell Biology. Liu, G.Y., Sabatini, 
D.M. mTOR at the nexus of nutrition, growth, ageing and disease. Nat Rev Mol Cell Biol 21, 183–203 (2020). 
https://doi.org/10.1038/s41580-019-0199-y. 
As protein synthesis is the most energy-consuming and resource-intensive process, especially 
for fast-growing cells (Buttgereit & Brand, 1995), it is tightly regulated by mTORC1, mainly 
via the two substrates 4E-BP1 and p70 S6 kinase 1 (S6K1). The role of phosphorylation of 4E-
BP1 has been described above. mTORC1 phosphorylates S6K1 on T389 (Burnett, Barrow, 
Cohen, Snyder, & Sabatini, 1998), which subsequently phosphorylates ribosomal protein S6 
(rpS6), a component of the small 40S subunit of ribosome. Though some evidence suggests 
that rpS6 phosphorylation promotes ribosome biogenesis via a transcriptional program 
(Chauvin et al., 2014), the function of rpS6 phosphorylation remains ambiguous. Notably, 
rapamycin preferentially inhibits S6K1 durably, where 4E-BP1 recovers its phosphorylation 
within 6 hours (Choo, Yoon, Sang, Roux, & Blenis, 2008). In paper I, more details about 
selective targeting while remaining strong potency for mTORC1 in a pre-clinical experiment 
to treat cancer were provided.  
1.3.3.1.2 Growth factors 
Growth factors and other mitogens can converge their effects on the tuberous sclerosis complex 
(TSC1/TSC2), which is a GTPase-activating protein (GAP) for conversion of active Rheb-GTP 
state to the inactive Rheb-GDP state (Inoki, Li, Xu, & Guan, 2003). Through this, TSCs act as 
essential upstream regulators of mTORC1 activation (Valvezan & Manning, 2019). For 
example, insulin/insulin-like growth factor 1 (IGF-1) can activate Akt, whereby TSC2 gets 
phosphorylated and dissociates from the lysosomal surface and relieve inhibition of Rheb and 





PRAS40 as mentioned above is an endogenous inhibitor of mTORC1, which associates with 
the scaffolding protein RAPTOR to abolish Rheb-driven mTORC1 activation (Haar, Lee, 
Bandhakavi, Griffin, & Kim, 2007; Sancak et al., 2007). PRAS40 can be phosphorylated not 
only by mTORC1 but also by Akt to relieve the inhibitory constraint of mTORC1 (Wiza, 
Nascimento, & Ouwens, 2012). How this coordination occurs remains to be elucidated.  
1.3.3.1.3 Amino acids 
Amino acids are among the major nutrients, and as early as in 1998, it was reported that leucine 
and arginine are required for mTORC1 activity (Hara et al., 1998). However, it is not until 
2008 that the identification of Rag proteins via binding RAPTOR revealed the mechanism of 
mTORC1 in response to amino acid availability (E. Kim, Goraksha-Hicks, Li, Neufeld, & 
Guan, 2008; Sancak et al., 2008). Specifically, Rags are a family of four related small 
guanosine triphosphatases (GTPases) (RagA, RagB, RagC, and RagD) and configured to be 
heterodimers, i.e. RagA or RagB is bound to RagC or RagD. They exist in two conformations 
being anchored to the lysosome by a pentameric Ragulator complex (comprising p18, p14, 
MP1, C7orf59 and HBXIP) (Bar-Peled, Schweitzer, Zoncu, & Sabatini, 2012; Sancak et al., 
2010; Su et al., 2017): RagA/B-GTP coupled with RagC/D-GDP is in an active state; RagA/B-
GDP coupled with RagC/D-GTP is inactive (Bar-Peled et al., 2012; Sancak et al., 2010; Shen, 
Choe, & Sabatini, 2017; Su et al., 2017). Rags, via interaction with RAPTOR, mediates the 
recruitment of mTORC1 from the cytosol to the lysosome, where Rheb stimulates the 
mTORC1 activity (Rogala et al., 2019). Currently, the study of amino acid sensors are still in 
exploration (Chantranupong et al., 2014; Saxton, Chantranupong, Knockenhauer, Schwartz, & 
Sabatini, 2016; Saxton, Knockenhauer, et al., 2016; Wolfson et al., 2016; Ye et al., 2015a).  
GCN2 is highly conserved from yeast to humans (Castilho et al., 2014), while mammalian 
GCN2 is less studied (Caballero-Molada et al., 2018; Li et al., 2018b; Ye et al., 2015b). Under 
amino acid deficiency, GCN2 is activated by the binding of increased levels of deacylated 
tRNAs (Lageix, Zhang, Rothenburg, & Hinnebusch, 2015). As outlined in section 1.3.2.1, 
GCN2 is one of four stress-sensing kinases that respond to ISR and phosphorylates eIF2α to 
reduce global protein synthesis, simultaneously inducing a transcriptional program via ATF4’s 
expression (Pakos‐Zebrucka et al., 2016). Sestrin2, a member of the Sestrin family of stress 
response proteins, which are emerging to be negative regulators of the Rag GTPases 
(Chantranupong et al., 2014; J. S. Kim et al., 2015; Parmigiani et al., 2014; Peng, Yin, & Li, 
2014), is pinpointed to be induced via GCN2-ATF4 pathway under amino acid starvation (Ye 
et al., 2015b). Combing with the essential role of Rag GTPases in recruiting mTORC1 to the 
lysosome, sestrin2 whereby disrupts mTORC1 localization to the lysosome and sustains 
mTORC1 suppression (Ye et al., 2015b). Nonetheless, how GCN2 activation and mTORC1 
inhibition are coordinated to regulate protein synthesis is still not clear. 
Collectively, nutrients and hormonal signals are converging on translation machinery via 




Figure 5: Regulatory network of the mTOR signaling pathway. 
Reprinted with permission from Springer Nature, Nature Reviews Molecular Cell Biology. Liu, G.Y., Sabatini, D.M. mTOR at 
the nexus of nutrition, growth, ageing and disease. Nat Rev Mol Cell Biol 21, 183–203 (2020). https://doi.org/10.1038/s41580-
019-0199-y. 
1.3.3.2 Oxygen level, and VHL loss of function impinging on mRNA translation 
For sensing oxygen levels, which is essential for cell growth and metabolism, prolyl 
hydroxylase domain protein (PHD) plays a critical role. PHD regulates hydroxylation of 
hypoxia-inducible factor α (HIFα), which is a transcription factor responsible for induction of 
genes involved in oxygen-independent glycolysis and angiogenesis for adaption of low oxygen 
condition (Gordan, Thompson, & Simon, 2007; Kaelin & Ratcliffe, 2008). PHD, as a member 
of dioxygenase family, uses molecular oxygen and α-ketoglutarate (α-KG) to hydroxylate the 
conserved prolyl residues in HIFα. Thereby, hydroxylated HIFα can be recognized by pVHL, 
which acts as a substrate recognition subunit of an E3 ubiquitin ligase. Recognized 
hydroxylated HIFα is ubiquitinated by the pVHL-E3 ubiquitin ligase and consequently gets 
cleared up by the proteasome system. Under normoxic condition, HIFα hydroxylation is 
dependent on the activity of PHD, resulting in rapid hydroxylation and degradation to maintain 
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a low HIFα level. Instead upon low oxygen, referred to as hypoxia, PHD activity is decreased 
due to the insufficient oxygen level. Therefore, HIFα is less hydroxylated and less degraded. 
Accumulated HIFα promotes gene expression necessary for adaption to this condition (Gordan 
et al., 2007; Majmundar, Wong, & Simon, 2010).  
Current knowledge of translational control in response to hypoxia has emphasized a rapid 
inhibition of protein synthesis at the acute phase and maintained repression at the chronic phase 
via eIF2α and eIF4F complex, respectively (Koritzinsky et al., 2006; Koumenis et al., 2002). 
The availability of eIF2-GTP-Met-tRNAi ternary complex is a key point for regulation of 
translation, as described in sections 1.2.1 & 1.3.2.1. Under hypoxia, phosphorylation of eIF2 
occurs within 1 hour due to a coordinated ER stress-activated PERK activation, which leads to 
inhibition of protein synthesis without any significant changes in transcription (Koumenis et 
al., 2002). Remarkably, phosphorylation of eIF2 reaches a maximum at 1-2 hours, and then 
declines regardless of the global translation inhibition. Furthermore, the phosphorylation is 
completely reversible upon re-oxygenation (Koumenis et al., 2002).  
Inhibition of mRNA translation during prolonged hypoxic exposure is mediated by eIF4F, 
which is an eIF2α-independent mechanism. It has been shown that HIFα also induces 
Regulated in DNA damage and development 1 protein (REDD1) expression (also known as 
RTP801 or DDIT4) which restores TSC2 activity, and thereby suppresses mTORC1 activity 
to regulate protein synthesis (Brugarolas et al., 2004). Thus, the second mediator in control of 
translation during hypoxia, eIF4F, is at least partially controlled by HIFα-REDD1-TSC1/2 
axis-dependent mTORC1 activity. There is also evidence that hypoxia inhibits mTORC1 
partially through AMP-activated protein kinase (AMPK) (Corradetti, Inoki, & Guan, 2005; 
Sofer, Lei, Johannessen, & Ellisen, 2005; Wouters et al., 2005). Seemingly, it remains unclear 
how the multifaceted modulators coordinate in response to prolonged hypoxia (Van Den 
Beucken, Koritzinsky, & Wouters, 2006).   
One specific context is VHL loss of function which is the most common genetic alteration in 
renal tumors, especially the most common histological type, clear-cell renal cell carcinoma 
(ccRCC). Inactivated VHL leads to constitutive HIF1α activation (Maxwell et al., 1999; Talks 
et al., 2000; Zhong et al., 1999), which may be expected to induce REDD1 and suppress 
mTORC1 activity. On the other hand, mTOR pathway is frequently hyperactivated in cases of 
ccRCC. Although the insensitivity and acquired resistance to rapalogs occurred in clinic, there 
was a study that reported observation of RCC with mutations in mTOR or related pathways 
benefiting from rapalogs (Kwiatkowski et al., 2016). In between of VHL and mTORC1, HIF 
may affect hyperactivated mTOR pathway or normal mTOR pathway in ccRCC differently 
depending on the status of VHL. Combining with the heterogeneous benefits of rapalogs in 
clinic and the lack of biomarkers for selection of RCC patients to rapalogs, it is necessary to 
look into the molecular mechanisms of interplay between VHL status and mTOR inhibition. 
In paper III, we specifically explored the VHL-associated translational control in response to 




1.4 DYSREGULATED TRANSLATION IN CANCER AND ITS THERAPEUTIC 
TARGETING 
Early studies noted there were changes in the amount of unique mRNA species associated with 
polysomes when comparing resting to growing cells (Williams & Penman, 1975), i.e. some 
mRNAs in resting cells were not associated to polysomes in growing cell and, vice versa. 
Nowadays, dysregulated translation in cancer has been extensively reviewed (Nathaniel 
Robichaud, Sonenberg, Ruggero, & Schneider, 2019; D. Ruggero, 2012; Silvera, Formenti, & 
Schneider, 2010). As discussed in section 1.3.2.2, aberrant eIF4F function is implicated in a 
range of tumor types (C. N. Chen, Hsieh, Cheng, Lee, & Chang, 2004; Coleman et al., 2009; 
Graff et al., 2009; Holm et al., 2008; Rosenwald et al., 1999; Salehi, Mashayekhi, & 
Shahosseini, 2007; R. Wang et al., 2009; S. Wang et al., 1999). Among all translation factors, 
overexpression of eIF4E has been shown to promote tumorigenesis and metastasis (Davide 
Ruggero et al., 2004; Wendel et al., 2004), while overexpression of 4E-BP1 (a suppressor of 
eIF4E) partially reverses tumorigenesis(Rousseau, Gingras, Pause, & Sonenberg, 1996).   
Several pathways, e.g. PI3K/mTOR, MEK-ERK, p38 MAPK impinge on the translation 
machinery, commonly on eIF4E, and thus affect translational output (Roux & Topisirovic, 
2012, 2018). Accordingly, targeting mRNA translation via blocking upstream signaling 
pathways or direct interference with components of translation machinery is an emerging and 
interesting option for future cancer treatment (Figure 6, Table 1). 
1.4.1 Targeting the mTOR pathway  
Dysregulation of the mTOR pathway has been linked to many human diseases, including 
cancer (Bhat, Sonenberg, & Gores, 2013; Guertin & Sabatini, 2007; Laplante & Sabatini, 
2012). As discussed in section 1.3.3.1, mTORC1 integrates a number of upstream signals onto 
the translation machinery. For instance, 4E-BP1, which is one direct substrate of mTORC1, 
controls the assembly of the eIF4F complex via binding eIF4E. Moreover, anti-tumor potency 
by suppressing this pathway is mainly achieved through hindering mTORC1 functionality 
(Janes & Fruman, 2010; Thoreen et al., 2009). During the past decades, mTOR inhibitors have 
been extensively developed. The first-generation inhibitors, rapamycin analogues, selectively 
inhibit mTORC1 via allosteric binding the FRB domain of mTOR in complex FKB12-
rapamycin (Figure 4). Two rapalogs, everolimus and temsirolimus have been approved by the 
Food and Drug Administration (FDA) for treating kidney and breast cancers in clinic (Basho 
et al., 2017; Chan et al., 2005; Vinayak & Carlson, 2013). Nonetheless, due to the insufficient 
inhibition of mTORC1 substrates (Faes, Demartines, & Dormond, 2017; Thoreen & Sabatini, 
2009), the efficacy of rapalogs as anti-tumor drugs is limited. Moreover, a durable inhibition 
of S6K1 triggers increased Akt activation due to the PI3K-Akt feedback loop (Faes et al., 2017) 
which accelerates the activation of oncogenic signaling pathways (Chaturvedi, Gao, Cohen, 
Taunton, & Patel, 2009; Rodrik-Outmezguine et al., 2011). The second-generation inhibitors 
bind the ATP-active site of mTOR (see Figure 4) and therefore inhibit both mTORC1 and 
mTORC2 (Benjamin, Colombi, Moroni, & Hall, 2011). In pre-clinical models, the anti-tumor 
efficacy of ATP-competitive TOR inhibitors are generally superior to rapalogs due to the 
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complete inhibition of mTOR and sustained inhibition of 4E-BP1 phosphorylation. However, 
complete inhibition of mTOR by the second-generation inhibitors can cause severe side effects 
and leads to reduced tolerance in the clinic because of kinase similarities between mTOR and 
other kinases such as PI3K (Benjamin et al., 2011). For example, MLN0128 showed limited 
clinical efficacy in a clinical Phase II trial due to dose reduction secondary to toxicity (Graham 
et al., 2018).  
Therefore, industry and academia strive to develop better mTOR inhibitors, aiming to maintain 
mTORC1 selectivity with high potency. Recently, the third-generation mTOR inhibitors 
emerged, the first one called RapaLink-1 (Rodrik-Outmezguine et al., 2016), which combines 
allosteric effects and targeting of the active site in a bivalent way. Although this inhibitor shows 
promising results (Fan et al., 2017), its selectivity is modest which motivated development of 
inhibitors with increased selectivity for mTORC1 over mTORC2. More details are provided 
under Paper I. 
1.4.2 Targeting the translation machinery  
There are already a number of therapeutic agents that efficiently target components (e.g. eIF4E, 
eIF4A) of the translation machinery (Chu & Pelletier, 2018; Hsieh & Ruggero, 2010; Pal, 
Safari, Jovanovic, Bates, & Deng, 2019; Sharp & Fan, 2021). Moreover, targeting mRNA 
translation holds promise as an anti-tumor strategy to overcome insensitivity or resistance 




Figure 6: Schematic representation of therapeutic targeting the translation machinery in 
cancer. Important drug targets of the translation machinery and compounds that target them 
are shown.  
Reprinted with permission from Springer Nature, Nature Reviews Drug Discovery. Bhat, M., Robichaud, N., Hulea, L. et 
al. Targeting the translation machinery in cancer. Nat Rev Drug Discov 14, 261–278 (2015). https://doi.org/10.1038/nrd4505 
1.4.2.1 Direct targeting of the eIF4F complex 
As described in section 1.2.1, eIF4E is critical for the assembly of eIF4F and its function. For 
targeting the eIF4F complex, antisense oligonucleotides (ASOs) against eIF4E have been 
developed. In mouse models, ASO strategies to suppress eIF4E have been well-tolerated and 
shown anti-tumor potential (DeFatta, Nathan, & De Benedetti, 2000; Lin et al., 2012; Rinker‐
Schaeffer, Graff, De Benedetti, Zimmer, & Rhoads, 1993). Another approach to interrupt 
eIF4F is via inhibiting the eIF4E-cap interaction. This is supported by the conclusion that eIF4E 
mutants which are defective in cap binding are not tumorigenic (Wendel et al., 2007). Thus, 
cap analogs (e.g. 4Ei-1) which inhibit cap-dependent translation have been designed (Ghosh et 
al., 2009). Overexpression of eIF4G (the scaffolding protein in eIF4F) and eIF4A (the RNA 
helicase in eIF4F) is also detected in several malignancies and is associated with disease 
progression (Shanhui Liang et al., 2014; Silvera et al., 2009). eIF4G binds not only eIF4E, but 
also mRNAs to stabilize the cap-eIF4E association (Moerke et al., 2007). Several agents 
including 4EGI-1, 4E1RCat and 4E2RCat were designed to inhibit the eIF4E-eIF4G interaction 
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(R. Cencic et al., 2011; Moerke et al., 2007) and showed promises in pre-clinical models (L. 
Chen et al., 2012; Mader, Lee, Pause, & Sonenberg, 1995). Hippuristanol, pateamine A, and 
silvestrol are three eIF4A inhibitors which inhibit translation and show pre-clinical efficacy in 
both in vitro and in vivo models (M.-E. Bordeleau et al., 2008; R. Cencic et al., 2013; Regina 
Cencic et al., 2009; Kuznetsov et al., 2009; Low et al., 2014; Malina, Mills, & Pelletier, 2012; 
Tsumuraya et al., 2011).  
1.4.2.2 Interrupt ternary complex formation  
In section 1.2.1, the role of TC in translation initiation is described. Although the biochemistry 
of TC formation and activity is well studied, its role in cancer biology and exploitation as an 
anti-tumor target is not as well understood as for the eIF4F. Increased phosphorylation of 
eIF2α, which is the substrate of stress-sensing kinases as noted above, can induce cell apoptosis 
(Donzé et al., 2004). Therefore, approaches aiming to increase eIF2α phosphorylation have 
been assessed for cancer treatment. These approaches include the development of salubrinal. 
(More details in Table 1, Figure 6). However, the toxicity of these compounds has been noted, 



















Table 1: Therapeutic agents targeting translation machinery in cancer (Bhat et al., 2015b; Chu & Pelletier, 2018; Sharp & 
Fan, 2021). 
Target Mechanism Name Category References 
eIF4E–Cap 
Interaction 
Inhibit eIF4E cap-binding 
activity 
4Ei-1 An N7-benzyl GMP 
tryptamine phosphoramidate 
pronucelotide 
(Wagner, Iyer, & McIntee, 2000) 
eIF4E:eIF4G 
Interaction 
4EGI-1 binds to eIF4E at a 
location removed from the 
eIF4G-binding site  
4EGI-1 
 
Compound (Moerke et al., 2007; 
Papadopoulos et al., 2014) 
 
Prevent the association of 




 (Regina Cencic et al., 2011) 
eIF4A Bind eIF4A Pateamine A (PatA) 
 
A naturally occurring 
metabolite isolated from the 
marine sponge Mycale 
hentscheli; 
 
(Northcote, Blunt, & Munro, 
1991) 
Prevent eIF4A from 
interacting with RNA without 
affecting ATP binding 
Hippuristanol  A polyoxygenated steroid first 
isolated from the gorgonian 
Isis hippuris; 
(M. E. Bordeleau et al., 2006; 
Higa, Tanaka, & Tachibana, 
1981; Higa, Tanaka, Tsukitani, & 
Kikuchi, 1981) 
 




Rocaglates originated from 
plants of the Aglaia genus. 
(Chambers et al., 2013) 
eIF4G Bind to eIF4G1 BI-69A11 
SBI0640756 (SBI-
756) 
AKT inhibitors (Gaitonde et al., 2009) 
(Feng et al., 2015) 
eIF2 Blocking dephosphorylation 
of phospho-eIF2α 
Salubrinal A more potent and soluble 
derivative (Sal003) 
(Robert et al., 2006) 
Prevent the binding of Met-
tRNAi
Met to eIF2 
NSC119889 
NSC119893 
Fluorescein derivatives  
 
(Robert et al., 2006) 
eIF2B Cause dimerization of eIF2B ISRIB (ISRIB-A1; 
ISRIB-A17) 
 (Sidrauski et al., 2013) 
(Sidrauski et al., 2015) 






1.5 METHODS TO STUDY TRANSLATION (LIMITED TO THIS THESIS) 
To monitor changes of translation efficiency (see definition in section 1.3.1), levels of 
translated mRNAs (i.e. mRNAs associated with ribosomes) are compared to total mRNA levels 
in the cytosol.   
As translation initiation is 
rate-limiting under most 
conditions, the number of 
translation initiation 
events per mRNA and unit 
time approximates the 
protein synthesis output, 
and can be assessed by the 
number of ribosomes 
associated with the 
mRNA (see section 1.3.1). 
Therefore, mRNAs can be 
separated by velocity 
sedimentation when 




typical polysome tracing 
plot is in Figure 7).  
 
Figure 7: A typical polysome tracing plot to see the shift of 
transcripts from being highly translated to being suppressed 
upon a starvation condition. 40S and 60S are subunits of one 
ribosome. 80S represents one ribosome formation. Green 
lines define different fractions which contain mRNAs being 
bond with different number of ribosomes, e.g. two 
ribosomes, three ribosome, etc. Under starvation, the 
polysome fractions will decrease compared with the non-
starved condition, whereas the 80S part will be increased, 
meaning the accumulation of monosome, which is a sign of 
translation efficiency decrease.  
1.5.1 Studies of translation for single mRNA species  
If the purpose is to detect changes in translation efficiency of specific mRNAs, mRNA from 
each fraction in Figure 7 can be collected for downstream quantification using e.g. Northern 
blotting or reverse transcription quantitative polymerase chain reaction (RT-qPCR). This could 
reveal a shift in the polysome-association for specific mRNAs across conditions indicating a 
change in their translation efficiency, i.e. a change in the number of associated ribosomes. 
Under stress conditions, most RNA species would shift from a heavy polysomal fraction to a 
light polysomal fraction, or even sub-polysomal fractions. For example, housekeeping genes 
(e.g. β-actin) are not affected to a similar extent as TOP mRNAs which drastically shift from 
heavy polysomal fractions to sub-polysomal fractions upon serum deprivation (Geyer, 
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Meyuhas, Perry, & Johnson, 1982). This dramatic decrease of polysome-association can be 
detected via protein synthesis output without altered mRNA level. Hence, to monitor how an 
RNA feature affects translation, like TOP motif, in Paper II, we developed a reporter with the 
RPL23-TOP motif, which could reflect translation changes under different conditions (more 
details will be discussed below).   
1.5.2 Transcriptome-wide studies of mRNA translation 
To study translation at a transcriptome-wide scale polysome profiling can be used. Polysome-
profiling uses RNA-sequencing (RNA-seq) to quantify mRNAs associated with >3 ribosomes, 
which are thought to be translated efficiently (Gandin et al., 2014). In parallel, cytosolic 
mRNAs are also collected. In this way, the final RNA-seq data analysis provides cytosolic 
mRNA-adjusted changes in polysome-associated mRNA levels downstream of altered 
translation efficiency. This method was recently optimized to sedimentate efficiently translated 
mRNAs on a sucrose cushion, which enabled transcriptome-wide studies of mRNA translation 
in small samples and dramatically reduced the experiment time (Shuo Liang et al., 2018).  
 
To enable analysis, 
analytical and 
computational approaches 
have also been developed 
(Oertlin et al., 2019). 
Anota2seq is based on 
anota, which was 
developed for polysome-
profiling data quantified 
using DNA-microarrays 
(Larsson, Sonenberg, & 
Nadon, 2010, 2011). 
Anota2seq analysis 
determines alteration in 
translation efficiency 
using a linear model. 
Analysis using Anota2seq 
categorizes mRNAs into 
different gene expression 
modes (Figure 8).  
 
Figure 8: One representative scatter plot of polysome-
associated mRNA vs. cytosolic mRNA log2 fold changes.  
Modified and Reprinted with permission from John Wiley and Sons, The EMBO 
Journal. Julie., Eric.,et.al Translational offsetting as a mode of estrogen receptor 




Ribosome profiling quantifies ribosome protected fragments and analyses translation by 
comparing changes in such fragments which cannot be explained by alterations in total 
cytosolic mRNA (Ingolia, Ghaemmaghami, Newman, & Weissman, 2009; McGlincy & 
Ingolia, 2017). However, as the RNase digestion only retains the ribosome-protected fragments 
(RPFs), the information about the number of ribosome association with mRNAs is lost. 
Nonetheless, it can provide information about the location of ribosome occupancy on mRNAs 
which enables studies aiming to find regulatory features of mRNA translation (Aeschimann, 
Xiong, Arnold, Dieterich, & Großhans, 2015).  
Moreover, the development of RNA-seq techniques also facilitates transcriptome-wide studies 
of mRNA translation. For instance, Smart-seq2 library preparation allows transcriptome 
analysis from single cells, which needs a very low amount of input RNA(Picelli et al., 2014). 
Recently, nano-cap analysis of gene expression (nanoCAGE) method specifically sequences 
the 5’UTR of transcripts, which can provide transcription start site (TSS) profiling of translated 
transcripts in combing with polysome profiling (Gandin et al., 2016). At the individual mRNA 
level, live cell imaging methods e.g. TRICK, NCT/SINAPS (Halstead et al., 2015; Morisaki et 
al., 2016; C. Wang, Han, Zhou, & Zhuang, 2016; Wu, Eliscovich, Yoon, & Singer, 2016; Yan, 
Hoek, Vale, & Tanenbaum, 2016) have also been developed to allow monitor live single-
molecule translation in a dynamic fashion.  
In this thesis, polysome profiling is used to reveal translational control under different contexts, 
i.e. effect of selective mTORC1 inhibitors on translatome (Paper I), translational control 
associated with VHL status in response to rapamycin (Paper III), and translational control of 
immune cell phenotype (Paper IV). In Paper II, translation of one subset of mRNAs, i.e. TOP 
mRNAs is explored with a developed reporter for finding modulators. 
 

















2 AIMS OF THIS THESIS 
Overall, this thesis aims to study mTOR-dependent regulation of mRNA translation in cancer. 
In study I, we aimed to examine the effects of newly developed mTORC1-selective bi-steric 
inhibitors on translatome.   
In study II, we aimed to develop a luciferase reporter for TOP-mRNAs, whose translation is 
very mTOR-sensitive to enable the identification of additional factors and pathways 
modulating such translation either dependent or independent of mTOR.  
In study III, we aimed to characterize the VHL-associated effects on mRNA translation in 
response to mTOR inhibition. 





















3 RESULTS AND DISCUSSION  
3.1 STUDY I--SELECTIVE INHIBITORS OF MTORC1 ACTIVATE 4EBP1 AND 
SUPPRESS TUMOR GROWTH 
PI3K-mTOR pathway affects a wide range of physiological functions and cellular activities. 
Dysregulation of this pathway due to genomic alterations plays an essential role in 
carcinogenesis and tumor progression (Chalhoub & Baker, 2009; Vivanco & Sawyers, 2002), 
and is the second frequently altered pathway after the p53 signaling pathway (Klempner, 
Myers, & Cantley, 2013). Thus, potent targeting of PI3K-mTOR has been an important 
therapeutic strategy in cancer (Janes & Fruman, 2010; Thoreen et al., 2009). The first-
generation mTOR inhibitors, rapalogs, have been applied in monotherapy or combination 
therapies (Benjamin et al., 2011; Gonzalez-Angulo et al., 2013). The mechanism whereby 
rapalogs inhibit mTOR is through the allosteric binding with the FKBP-rapamycin binding 
(FRB) domain of mTOR (see Figure 4). Structural distinctions of components between 
mTORC1 and mTORC2 (see Figure 4) offer the basis for rapalogs with higher selectivity of 
mTORC1 over mTORC2. However, such inhibition (Choo et al., 2008; Sarbassov et al., 2006) 
is limited due to insufficient targeting of mTORC1 downstream substrates, such as 4EBP1 and 
S6K (Bissler et al., 2008; Buti, Leonetti, Dallatomasina, & Bersanelli, 2016; Vinayak & 
Carlson, 2013). The second-generation mTOR inhibitors are designed to compete with ATP in 
the catalytic site of mTOR, thus suppressing both mTORC1 and mTORC2 (Zhou & Huang, 
2012). Yet, the clinical benefits remain unsatisfying (Graham et al., 2018; Powles et al., 2016). 
Recently, a third-generation inhibitor, RapaLink-1 (Rodrik-Outmezguine et al., 2016), which 
exploits the unique juxtaposition to covalently link two drug-binding pockets, was reported to 
overcome the resistance to existing first- and second-generation inhibitors. Of note, RapaLink-
1 inhibits mTOR more potently, but still low selectivity for mTORC1 (only three- to four-fold) 
(Fan et al., 2017; Rodrik-Outmezguine et al., 2016). 
With this prototype, RapaLink-1, we modified the essential core moieties to produce 
compounds with varying mTORC1/2 selectivity. From the biochemical and pharmacological 
data, the selectivity of these compounds was identical with the affinities of allosteric 
(mTORC1) and orthosteric (mTORC1 and mTORC2) components for their respective binding 
sites. Among those, three mTORC1-selective bi-steric inhibitors (BiS-13x, BiS-31x, and BiS-
35x) were further evaluated for their biological characterization compared with pan-mTOR 
active-site (MLN0128) and bi-steric (BiS-NS) inhibitors or rapamycin.  
The basis of selectivity of mTORC1 over mTORC2 relied on the formation of FKBP12-
mTOR-inhibitor ternary complex. To verify if our modular approach affects the spectrum of 
kinases, a mass spectrometry-based kinome screen (Patricelli et al., 2007) was conducted and 
analysis of kinase interactions found interaction occurring solely with mTOR in BiS-NS and 
BiS-31x. Even though BiS-13x and BiS-35x were observed to interact with certain kinases, the 
extent was much lower than that in pan-mTOR active-site inhibitors (MLN0128 and PP242). 
These results indicated mTORC1-selective bi-steric inhibitors would not significantly inhibit 
other kinases and have less off-target effects.  
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The anti-tumor effect in pre-clinical in-vitro models showed that BiS-13NS and BiS-13x have 
a higher potency than BiS-31x and BiS-35x, as well as MLN0128, which was consistent with 
the induced caspase activity. BiS-35x, while showing the least potency among bi-steric 
selective inhibitors, still induced higher caspase activity at a concentration (100 nM) than 
rapamycin (1 uM). Importantly, from the in vitro results, bi-steric mTORC1-selective 
inhibitors did not induce receptor tyrosine kinase expression, which was due to induced AKT 
activition. This might be the molecular basis for the reduced glucose intolerance of selective 
inhibitors observed in vivo (more details below).   
To verify the 4EBP1 dependency of mTORC1-selective bi-steric inhibitors in suppressing 
tumor growth, we made the variant, 4EBP1-A, which was a doxycycline-inducible 4EBP1 
mutant protein. It showed 4EBP1-A was insensitive to inhibition of mTOR, and maintained a 
constitutively active form of 4EBP1 upon mTOR kinase inhibition. In-vitro results showed that 
effective inhibition of 4EBP1 phosphorylation was sufficient to suppress tumor proliferation. 
Further, we also used CRISPR/Cas9 editing and shRNA techniques to delete or knockdown 
4EBP1 from the in vitro cancer cell line to examine the necessity of active 4EBP1 in such 
inhibition of tumor growth. As expected, effects of these inhibitors on eIF4F complex 
formation and eIF4F-sensitive translation were attenuated, yet only a modest reduction of anti-
proliferation effect upon pan-mTOR inhibitor (RapaLink-1) and mTORC1-selective bi-steric 
inhibitors (BiS-13x and BiS-35x) was observed. A similar pattern was also observed in 
4EBP1/2 DKO MEFs upon MLN0128, and BiS-13x, BiS-35x compared to 4EBP1/2 wild-type 
MEFs. Taken together, 4EBP1 activation is necessary for maximal inhibition of tumor 
proliferation by both pan-mTOR inhibitors and mTORC1-selective bi-steric inhibitors, but not 
necessary for a significant anti-proliferation activity.  
 
 
Figure 9: Representative polysome 
tracings of inhibition with indicated 
conditions.  
Accordingly, transcriptome-wide 
comparisons of translation efficiencies 
were obtained using polysome profiling 
(section 1.5.2, Figure 9) between active-
site inhibitor MLN0128 and two mTORC1-
selective bi-steric inhibitors, BiS-13x and 
BiS-35x. Notably, the effects on mRNA 
translation and total mRNA levels were 
identical for BiS-13x, BiS-35x as compared 
to MLN0128. This therefore supports that 
mTORC1-selective bi-steric inhibitors 
show similar potency as an active-site 
inhibitor for mTORC1 inhibition, while 
having higher selectivity for
mTORC1 over mTORC2. Moreover, these studies also indicate that mTORC1, but not 
mTORC2 is responsible for the translational reprogramming downstream of mTOR inhibition.  
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Further, pan-mTOR inhibitors (MLN0128 and BiS-NS) and mTORC1-selective inhibitors 
(BiS-13x and BiS-31x) were evaluated in an MCF7 subcutaneous xenograft model using an 
administration schedule previously used for RapaLink-1 (Rodrik-Outmezguine et al., 2016). 
Apart from MLN0128, the inhibitors all showed sustained inhibition of phosphorylation of 
4EBP1 in plasma. Moreover, BiS-13x and BiS-31x induced increased phosphorylation of AKT 
on S473 site at 4 hours of administration (sustained for at least 72 hours) which was much 
earlier than the pan-mTOR inhibitor, BiS-NS. Hence, the in vivo results for mTORC1-selective 
bi-steric inhibitors were identical with in-vitro experiments, with selective inhibition of 
p4EBP1 while inducing pAKT S473. And the anti-tumor effect in vivo of BiS-13x and BiS-
31x was also comparable with MLN0128 and correlated with inhibition of p4EBP1, but not 
pAKT S473. Meanwhile, mice body weights were also recorded as a measure of drug toxicity. 
It turned out compounds with higher selectivity for mTORC1 showed better tolerance, with 
maximum weight loss by BiS-13x and BiS-31x of 10% and 5%, respectively. A similar 
observation was also shown in the xenograft model with another breast cancer cell line.  
As discussed above, AKT inhibition by pan-mTOR inhibitors, particularly, inhibition of AKT 
S473 phosphorylation may be related with glucose intolerance upon PI3K inhibition (Hagiwara 
et al., 2012). When mice were administered to the candidate mTORC1-selective bi-steric 
inhibitors and pan-mTOR inhibitors, glucose levels in the blood were traced with a two-day 
glucose tolerance test (GTT) to monitor the immediate and delayed effects. Significantly, 
MLN0128 delayed the return of glucose levels to baseline after both the first and second 
glucose challenge, and the modified-version of RapaLink-1, BiS-NS also had an effect on 
glucose recovery at the delayed phase. In contrast, in mice administered with mTORC1-
selective bi-steric inhibitors, BiS-13x and BiS-31x, blood glucose levels returned to baseline 
within one or two hours after the challenge, showing better glucose tolerance, due to the relief 
of mTORC2-dependent inhibition of AKT. However, the association needs further 
experimental validation.  
In summary, mTORC1-selective bi-steric inhibitors developed via modular approach are, to 
our knowledge, the first compounds to achieve significant inhibition selectivity of mTORC1 
over mTORC2, whereby suppression of 4EBP1 was sufficient for anti-tumor activity in pre-
clinical models and caused less glucose intolerance. As dissected using polysome profiling for 
comparisons of different mTOR inhibitors, targeting of mTORC1 provided a translational 
reprogramming associated with the antitumorigenic effects of mTOR inhibition.     
 
3.2 STUDY II--IDENTIFICATION OF KINASES MODULATING TRANSLATION 
OF MRNAS WITH TERMINAL OLIGO-PYRIMIDINE (TOP) MOTIFS 
Regulation of gene expression via modulation of translation efficiencies is an important means 
to shape the protein repertoire during adaption to internal or environmental alterations (see 
section 1.3). Terminal oligopyrimidine (TOP) mRNA is a group of transcripts with a specific 
sequence feature in their 5’UTR, i.e. a stretch of uninterrupted pyrimidines. Such sequence 
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feature confers the sensitivity of TOP mRNA to regulation of the mTOR signaling pathway. 
However, other regulators acting dependently or independently of mTOR pathway are  
incompletely characterized. LARP1, as discussed above, acts as a negative regulator of TOP 
mRNA translation downstream of mTORC1. Yet, its depletion could not completely re-depress 
the inhibition on TOP mRNA translation by mTOR inhibitors such as rapamycin or torin1. 
This suggests that other regulators may also play a role in such regulation. Therefore, a precise 
and sensitive reporter for TOP mRNA translation in combination with a kinome-wide siRNA-
based screening strategy was implemented for the exploration of candidate regulators.  
 
 
Figure 10: A map of the pGL4.13[RPL23-
luc2CP/SV40/Neo] reporter plasmid. 
 
To generate a reporter for TOP mRNA translation, we 
generated the pGL4.13[RPL23-luc2CP/SV40/Neo] 
vector (Figure 10). Precisely, the 5’UTR from one classical TOP mRNA, RPL23, was 
positioned at the transcript start site (TSS) of the SV40 promoter. This was further verified 
using the 5’ rapid amplification of cDNA ends (RACE) approach (Figure 11). In fact, this step 
was challenging as the TSS needed to be precise to include a cytosine at the first position 
whereas this is usually not required when constructing expression vectors. Moreover, a stably 
transfected cell line was also established and the response of the reporter under alterations in 
mTOR activity was evaluated using insulin stimulation in the presence or absence of an mTOR 
inhibitor torin1. This revealed that the reporter vector could detect changes in the protein levels 
independent of mRNA abundance (Figure 12), a hallmark of TOP mRNAs following 




Figure 11: 5’RACE-based validation of expression of luc2CP mRNA with the TOP motif from 
RPL23 at the +1 position. The position of the TOP motif immediately follows the poly-G stretch 
which marks the TSS in 5’RACE (upper panel). The entire RPL23 5’UTR is indicated relative 
to the start codon for the luc2CP gene (lower panel). 
 
 
Figure 12: (left) luc2CP mRNA levels were measured under different conditions and 
normalized to -actin (mean and standard deviations from 3 independent experiments are 
shown) (right) Luciferase activity following expression of the RPL23-luc2CP reporter were 
quantified under the same conditions as in (left). Mean and standard deviations from 3 
independent experiments are shown. 
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Next, we applied a cell-based assay for screening of possible regulators modulating translation 
of TOP mRNA. Consistent with current knowledge regarding the role of LARP1 in regulation 
of TOP mRNA (Fonseca et al., 2015b; Lahr et al., n.d.; Philippe et al., 2018), LARP1 was 
identified as a negative regulator in our screen. As expected, the silencing of Raptor showed a 
significant decrease in TOP mRNA translation. Through this approach, multiple kinases were 
identified as candidate regulators of TOP mRNA translation. Herein, we focused on a few 
previously suggested or uncharacterized regulators of TOP mRNA translation. Following 
reduced levels of specific amino acids such as cysteine/cystine, GCN2 is activated and 
catalyzes eIF2α phosphorylation, thereby inducing the expression of genes such as ATF4. 
Recently, it was reported that GCN2-eIF2α axis controls TOP mRNAs translation (Li et al., 
2018a). Interestingly, in our assessment, depletion of GCN2 by siRNA also induced increased 
TOP mRNA translation under serum starvation as well as mTOR inhibition. Moreover, such 
regulation was also not dependent on LARP1, according to the dual depletion of GCN2 and 
LARP1, whereas increased translation by siGCN2 was abolished by dual depletion of GCN2 
and Raptor. Although these studies suggest GCN2 as part of a parallel pathway controlling 
TOP mRNA translation, the detailed mechanisms remain to be elucidated. Similarly, we also 
identified MAPK13, a member of MAP kinase family, which also appeared to be a negative 
regulator of TOP mRNA translation.  
 
3.3 STUDY III--IN VITRO CHARACTERIZATION OF VHL DEPENDENT MRNA 
TRANSLATION IN RENAL CELL CARCINOMA 
mRNA translation is regulated under low oxygen level (see section 1.3.3.2). In fact, most solid 
tumors experience transient or prolonged low oxygen supply during progression due to 
abnormal angiogenesis. In the specific context of renal cell carcinoma, the most common 
genetic alteration is loss of function in VHL. Being the tumor suppressor, pVHL is responsible 
for the degradation of HIF, whereas loss of VHL can lead to increased HIF expression even 
under normal oxygen condition. In paper III, we used in vitro RCC4 cell model to compare the 
effect of VHL in combination with polysome profiling to dissect how VHL loss affects mRNA 
translation. Although rapalogs, everolimus and temsirolimus, have been approved by FDA for 
a systematic treatment of RCC, whether patients harboring different mutations or other 
biomarkers respond differently to rapalogs is not well understood. One cohort study 
(Kwiatkowski et al., 2016), reported that patients with mutations in mTOR or its suppressor 
TSC1/2 in metastatic RCC patients benefited more from rapalogs. But, among responders, 24 
out of 43 were identified without mTOR pathway mutation. To figure out whether VHL status 
also has an impact on response to rapalogs, we treated VHL-proficient and VHL-deficient cell 
lines with rapamycin, and applied polysome-profiling in conjunction with anota2seq analysis 
to dissect transcript-selective translation modes.  
By comparing VHL-proficient RCC to VHL-deficient RCC, wide-spread VHL-associated 
modulation of gene expression at the mRNA level as well as the translation level was revealed. 
In particular, we sought to address whether the rapamycin response depends on VHL status. 
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As shown in Figure 13, although VHL-proficient cells showed numerous alterations in 
cytosolic mRNA level following 2 h of rapamycin treatment (marked in light blue and dark 
blue), their polysome-association remained largely unaltered. Such genes therefore show 
buffering at the level of translation. In contrast, a set of genes (marked in orange and dark red) 
did not change their cytosolic mRNA abundance but showed altered levels of polysome-
associated mRNA. Such transcripts were regulated via changes in translation independent of 
cytosolic mRNA abundance. Only a small subset of genes in VHL-deficient cells were down-
regulated in the polysome-associated mRNA level by rapamycin. Similarly, we assessed 16 h 
rapamycin treatment in a similar fashion (Figure 14). More genes were being disturbed by 
rapamycin in VHL-deficient cells. Functionally, genes uniquely sensitive to rapamycin in 
VHL-proficient cells, encoded proteins which were not significantly annotated to GO terms or 
KEGG pathways except for the interleukin-1-mediated signaling pathway. Of note, upon 
prolonged rapamycin treatment, genes which were translationally induced in response to 
rapamycin only in VHL-proficient cells were significantly enriched in immunity-related terms 
and important signaling pathways such as neurotrophin signaling pathway. In turn, genes which 
were translationally suppressed in response to rapamycin only in VHL-deficient cells were 
enriched in nucleosome- or chromatin-assembly related terms. In summary, genes in VHL-
proficient cells were not present in VHL-deficient cells in response to rapamycin, vice versa, 
were identified, and enriched with distinct functionalities. These studies therefore revealed 
ample regulation of translation depending on VHL and rapamycin in RCC.   
 
Figure 13: Visualization of rapamycin-sensitive gene expression following 2 h of serum 






Figure 14: Similar to Figure 13 but assessing rapamycin-sensitive gene expression following 
16 h of serum stimulation in presence or absence of rapamycin. 
 
3.4 STUDY IV--MNK2 GOVERNS THE MACROPHAGE ANTIINFLAMMATORY 
PHENOTYPE 
The role of eIF4F formation in regulating cap-dependent translation has been described in 
section 1.3.2.2. 4EBP1, as the suppressor of the key component eIF4E in the eIF4F complex, 
is modulated downstream of mTOR signaling pathway. mTOR promotes phosphorylation of 
4EBP1, and whereby eIF4E gets released to associate with eIF4G and eIF4A to form the eIF4F 
complex. Another modulator of eIF4E function is MNK1/2 which is responsible for 
phosphorylation of eIF4E. In paper IV, we observed tumor-weight-associated changes in 
mRNA translation in tumor-associated macrophages (TAMs). During tumor growth, there is a 
shift in the TAM population from a predominantly proinflammatory phenotype toward an 
antiinflammatory phenotype (Figure 15). Interestingly, further validation revealed that the 
MNK2/eIF4E but not the mTOR/4EBP axis controlled expression of transcripts encoding 
proteins related with the antiinflammatory phenotype of TAM. Accordingly, modulating 
MNK2/eIF4E via cercosporamide (chemical MNK inhibitors), depletion of MNK2 by 
lentiviral vectors encoding shRNAs targeting MNK2, or mutation of the MNK1/2 
phosphorylation site on eIF4E in ex vivo/in vivo setups, showed almost identically increased 
activation of CD8+ T cells.  
Tumor cells, especially in solid tumors, are always surrounded by tumor microvessels and 
immune cells in the stroma, constituting the tumor microenvironment (TME). Cross-talk 
between cancer cells and immune cells plays a decisive role in tumor progression and immune 
activity (Hinshaw & Shevde, 2019), which underlies the basis of immunotherapy in cancer 
treatment. Combining with the finding in paper I that activation of 4EBP1 is sufficient for 
maximal inhibition of proliferation by mTORC1-selective bi-steric inhibitors, but is not 
necessary for significant anti-proliferative activity, it seems eIF4F activity mediated by eIF4E 
phosphorylation could be another targetable component for achieving improved anti-tumor 
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activity. Moreover, such inhibition may have a potential role in increasing cytotoxic CD8+ T 
cell activity. Results from paper IV indicated that combined shMNK2 depletion and MNKi 
inhibition on TAM did not induce higher IFNγ production in CD8+ T cells than either of the 
two strategies. This suggested a ceiling for MNK2/eIF4E axis-dependent induction of CD8+ T 
cell activity that existed in TAM. However, we did not look further into how dual targeting of 
4EBP1 and phosphorylation of eIF4E affect tumor cell proliferation or immune cell cytotoxic 
activity. Nonetheless, we believe phosphorylation of eIF4E could partially contribute to the 
suppressive immune response via TAM functional phenotype shift during tumor growth.  
 










4 CONCLUSION AND FUTURE PERSPECTIVE 
Gene expression is orchestrated at multiple levels in eukaryotic cells. This thesis specifically 
provides insights into the role of mRNA translation, which acts as the distal step in conveying 
genomic messages to functional protein molecules. One focus is how the translation of 
transcripts is modulated via the mTOR pathway independently of their mRNA levels. 
Importantly, this control is preferential for transcripts with distinct structural and/or nucleotide-
sequence features. Functionally, control of those transcripts’ translation has profound 
biological consequences by reshaping the proteome towards a malignancy, an altered 
functional phenotype, or acquired resistance to treatment. Accordingly, elegant interrogation 
of mRNA translation through mTOR-mediated control or other pathways could open new 
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